Login to Your Account

Prostate Drug Just in Time?

$650M Aragon Buyout Brings J&J's Replacement for Zytiga

By Randy Osborne
Staff Writer

Tuesday, June 18, 2013

Johnson & Johnson's (J&J) planned takeover of Aragon Pharmaceuticals Inc. for $650 million in cash and $350 million more in potential milestone payments brings aboard the Phase III-ready ARN-509 for castration-resistant prostate cancer (CRPC) behind the pharma firm's approved androgen inhibitor Zytiga (abiraterone acetate) for the same indication.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription